This report was first published by Endpoints News. To see the original version, click here
As WuXi AppTec’s manufacturing revenue recovers, it said it is selling its clinical research services business in China to a Singapore-headquartered private equity firm.
WuXi AppTec announced on Monday that its contract research organization (CRO) WuXi Clinical and its separate site management unit WuXi MedKey are set to go to Hillhouse Investment Management. No financial details were given. Hillhouse has offices in Singapore, Hong Kong, Beijing and Shanghai, as well as in New York and London.
您已閱讀20%（587字），剩余80%（2352字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。